$RVTY · REVVITY, INC.
Revvity reported Q3 FY2026 results: revenue of $728.9M, GAAP EPS of $0.56, and adjusted EPS of $1.38. The company raised full-year 2026 guidance to pro forma revenue of ~$2.86B and pro forma adjusted EPS of $5.40-$5.45. Separately, Revvity filed pro forma financials reflecting the planned sale of its China Immunodiagnostics business for up to $200M, expected to close by end of 2027.
- Q3 revenue of $728.9M (+4.3% YoY) with pro forma organic revenue growth of 7%
- Adjusted EPS of $1.38 vs $1.18 prior year; GAAP EPS of $0.56 vs $0.41
- Life Sciences segment pro forma organic revenue grew 9% YoY to $380M
- FY2026 guidance raised: pro forma revenue ~$2.86B, pro forma adjusted EPS $5.40-$5.45
- China IDX divestiture for up to $200M expected to close by end of 2027; $55M loss on disposition booked
Extended-hours trading shows RVTY at $164.06, up +8.18% vs the $151.65 regular close, indicating strong positive reaction to the beat-and-raise quarter. The $16.92B market cap company delivered broad-based growth with both segments expanding margins.
Beat-and-raise quarter with 7% pro forma organic revenue growth, margin expansion across both segments, and a raised full-year outlook signals accelerating momentum for the $16.92B life sciences tools company.
Revvity's 7% pro forma organic growth and margin expansion to 29.4% adjusted operating margin outpaces the broader life sciences tools sector, which has been navigating mixed end-market demand. The China IDX divestiture mirrors peers simplifying geographic exposure.
China IDX sale carries execution risk — closing not expected until end of 2027, subject to regulatory approvals and conditions. The $55M loss on disposition and pro forma adjustments reflect estimates that may change. Tariff increases and global economic/political fluctuations flagged as ongoing risks.